See more : LF Capital Acquisition Corp. II (LFACW) Income Statement Analysis – Financial Results
Complete financial analysis of Amyris, Inc. (AMRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amyris, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- DKS Co. Ltd. (4461.T) Income Statement Analysis – Financial Results
- The Indian Card Clothing Company Limited (INDIANCARD.BO) Income Statement Analysis – Financial Results
- NDR Auto Components Limited (NDRAUTO.NS) Income Statement Analysis – Financial Results
- Guolian Securities Co., Ltd. (601456.SS) Income Statement Analysis – Financial Results
- Shenzhen Kexin Communication Technologies Co.,Ltd (300565.SZ) Income Statement Analysis – Financial Results
Amyris, Inc. (AMRS)
About Amyris, Inc.
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.85M | 341.82M | 173.14M | 152.56M | 80.42M | 143.45M | 77.19M | 34.15M | 43.27M | 41.12M | 73.69M | 146.99M | 80.31M | 64.61M | 13.89M |
| Cost of Revenue | 258.67M | 155.14M | 87.81M | 76.19M | 38.91M | 63.83M | 56.68M | 37.37M | 33.20M | 38.25M | 77.31M | 155.62M | 70.52M | 60.43M | 10.36M |
| Gross Profit | 11.18M | 186.68M | 85.33M | 76.37M | 41.51M | 79.62M | 20.51M | -3.22M | 10.07M | 2.87M | -3.62M | -8.62M | 9.80M | 4.18M | 3.53M |
| Gross Profit Ratio | 4.14% | 54.61% | 49.28% | 50.06% | 51.62% | 55.50% | 26.58% | -9.43% | 23.27% | 6.97% | -4.91% | -5.87% | 12.20% | 6.47% | 25.40% |
| Research & Development | 110.22M | 94.29M | 71.68M | 71.46M | 68.69M | 56.84M | 51.41M | 44.64M | 49.66M | 56.07M | 73.63M | 87.32M | 55.25M | 38.26M | 30.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 493.63M | 257.81M | 137.07M | 126.59M | 86.92M | 63.03M | 47.72M | 56.26M | 55.44M | 57.05M | 78.72M | 83.23M | 40.39M | 23.56M | 16.62M |
| Other Expenses | 0.00 | -38.07M | -89.16M | -20.15M | 1.36M | -956.00K | -45.37M | -114.18M | -30.00M | -20.86M | -45.63M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 603.84M | 352.10M | 208.75M | 198.05M | 155.61M | 119.88M | 99.13M | 105.62M | 105.10M | 113.12M | 152.35M | 170.55M | 95.64M | 61.82M | 46.93M |
| Cost & Expenses | 862.51M | 507.24M | 296.56M | 274.23M | 194.52M | 183.71M | 155.81M | 143.00M | 138.30M | 151.37M | 229.66M | 326.16M | 166.16M | 122.25M | 57.29M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 258.00K | 264.00K | 387.00K | 162.00K | 1.47M | 1.54M | 1.54M | 448.00K | 1.38M |
| Interest Expense | 24.73M | 25.61M | 47.95M | 58.67M | 39.27M | 36.16M | 37.63M | 78.85M | 28.95M | 9.11M | 4.93M | 1.54M | 1.44M | 1.22M | 377.00K |
| Depreciation & Amortization | 27.27M | -25.38M | -77.04M | -20.15M | 4.92M | 11.36M | 11.37M | 12.92M | 14.97M | 16.64M | 14.57M | 11.08M | 7.28M | 5.78M | 2.63M |
| EBITDA | -514.21M | -190.80M | -200.46M | -141.83M | -112.74M | -41.22M | -115.83M | -118.46M | -225.62M | -5.61M | -200.13M | -166.55M | -81.53M | -51.42M | -39.40M |
| EBITDA Ratio | -190.55% | -55.82% | -115.78% | -92.97% | -140.19% | -28.73% | -150.05% | -346.86% | -521.36% | -13.64% | -271.56% | -113.31% | -101.51% | -79.58% | -283.58% |
| Operating Income | -592.67M | -165.42M | -123.42M | -121.67M | -120.95M | -40.26M | -85.92M | -148.53M | -99.83M | -119.62M | -201.82M | -179.17M | -83.79M | -63.41M | -43.40M |
| Operating Income Ratio | -219.63% | -48.39% | -71.29% | -79.76% | -150.40% | -28.07% | -111.31% | -434.90% | -230.69% | -290.90% | -273.86% | -121.89% | -104.33% | -98.14% | -312.41% |
| Total Other Income/Expenses | 54.04M | -106.89M | -200.43M | -120.46M | -28.16M | -36.84M | -10.86M | -69.05M | 102.49M | -116.14M | -3.23M | 213.00K | 2.96M | -1.39M | 857.00K |
| Income Before Tax | -538.63M | -272.31M | -323.85M | -242.14M | -211.35M | -77.10M | -86.78M | -217.58M | 2.66M | -235.75M | -205.05M | -178.96M | -80.83M | -64.80M | -42.54M |
| Income Before Tax Ratio | -199.60% | -79.67% | -187.05% | -158.72% | -262.81% | -53.75% | -112.42% | -637.09% | 6.15% | -573.35% | -278.25% | -121.75% | -100.64% | -100.30% | -306.24% |
| Income Tax Expense | -2.70M | -8.11M | 293.00K | 629.00K | -50.95M | 295.00K | 553.00K | 468.00K | 495.00K | -847.00K | 981.00K | 552.00K | -3.98M | 877.00K | -207.00K |
| Net Income | -535.93M | -264.20M | -324.14M | -242.77M | -211.35M | -77.39M | -87.33M | -217.95M | 2.29M | -235.11M | -205.14M | -178.87M | -81.87M | -64.46M | -41.86M |
| Net Income Ratio | -198.60% | -77.29% | -187.22% | -159.13% | -262.81% | -53.95% | -113.14% | -638.16% | 5.28% | -571.78% | -278.37% | -121.69% | -101.94% | -99.77% | -301.35% |
| EPS | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -5.49 | -25.75 | 0.45 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| EPS Diluted | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -4.95 | -25.75 | 0.28 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| Weighted Avg Shares Out | 339.33M | 292.34M | 203.60M | 101.37M | 60.36M | 32.25M | 15.90M | 8.46M | 5.23M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
| Weighted Avg Shares Out (Dil) | 339.33M | 292.67M | 203.60M | 101.37M | 60.36M | 32.25M | 17.64M | 8.46M | 8.12M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
Amyris' Vertically-Integrated Business Model Transitioning From Investment Mode To Payoff Mode
Amyris' disruptive vertically-integrated business model should deliver favorable results beginning in H2 2022, linking synthetic biology, clean chemistry, precision fermentation, scaling, & hero ingredients with consumers, partners, & retailers. After spending $2+ billion over 15+ years developing revolutionary science, Q3 startups of...
Amyris: Revenues Need To Catch Expenses
There are high hopes that Amyris' Barra Bonita plant will rein in costs and improve the company's profitability. Fermentation is just one cost component though, meaning Barra Bonita will only have a limited impact, particularly on the consumer business.
3 Short Squeeze Penny Stocks To Watch Before Next Week
Short squeeze penny stocks to watch. The post 3 Short Squeeze Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Tech Stocks at the Top of Our Watchlists
This basket of infrastructure software, technical instrument, and specialty chemicals stocks looks like a good value.
3 Stocks Wall Street Thinks Could Triple Your Money or Better
Find out why the pros think these stocks could gain 200% or better.
AMYRIS PARTICIPATES IN INVESTOR CONFERENCES ON MAY 23, 24 AND 25, 2022
EMERYVILLE, Calif. , May 23, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that management is participating in fireside chats at the...
Better Buy: Gingko Bioworks vs. Amyris
Which of these fallen stocks has the best chance of recovery?
Amyris: A Question Of Agency Costs
Amyris' cash burn is currently high and their balance sheet weak, placing them in a vulnerable position as sentiment deteriorates. The business continues to expand rapidly, but margin improvements have stalled as investments have increased and supply constraints have elevated...
Amyris (AMRS) Earnings and Revenues Lag Estimates in Q1
Amyris (AMRS) sees strong revenues in its consumer segment in Q1 driven by growth of its legacy brands and strong contribution from new brands.
Amyris: Elevated Cash Usage Causes Investors To Head For The Exits
Discussing sell-off in the shares after the company's Q1 report revealed a much higher cash usage than anticipated by market participants. Even when assuming cash usage to trend down for the remainder of the year, Amyris would likely run out...
Source: https://incomestatements.info
Category: Stock Reports